RALEIGH — BioDelivery Sciences, a Raleigh-based pharmaceutical company, has filed a patent trademark lawsuit against four other companies, alleging the defendants have infringed upon a patent for its pain management drug Belbuca.
Biodelivery Sciences
In a lawsuit filed in Delaware, BioDelivery Sciences claims that Chemo Research SL, Insud Pharma SL, Intelgenx Corporation and Intelgenx Technologies Corporation have infringed upon two of BioDelivery’s patents for Belbuca.
The patents expire in 2027 and 2032.
The company settled another patent lawsuit against Teva Pharmaceuticals for the same drug in early 2018. The settlement will allow Teva Pharmaceuticals to begin selling a generic version of the drug in the U.S. in 2027.
BioDelivery Sciences stated that it plans to “vigorously defend its intellectual property against assertions of invalidity.”
BioDelivery Sciences utilizes technology and other drug delivery technologies to develop and commercialize new applications of proven therapies aimed at addresses important unmet medical needs.
The company’s products, such as Belbuca, address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, and opioid dependence.
This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism
